Mitochondrial DNA impairment in nucleoside reverse transcriptase inhibitor-associated cardiomyopathy

Chemical Research in Toxicology

Volumn 21, Issue 5, 2008, Pages 990-996

  Kohler, James J ^a   Hosseini, Seyed H ^a   Lewis, William ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2',3' DIDEOXY 2' FLUOROADENOSINE; ABACAVIR; DIDANOSINE; FIALURIDINE; LAMIVUDINE; MITOCHONDRIAL DNA; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; ZALCITABINE; ZIDOVUDINE; NUCLEOSIDE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; CARDIOMYOPATHY; CARDIOVASCULAR RISK; CHRONIC DISEASE; DRUG ACTIVITY; DRUG MECHANISM; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOST CELL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNITY; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; REVIEW; RISK FACTOR; ANIMAL; ARTICLE; CHEMICALLY INDUCED DISORDER; ENZYMOLOGY; GENETICS; METABOLISM;

ANIMALS; CARDIOMYOPATHIES; DNA, MITOCHONDRIAL; HIV INFECTIONS; HUMANS; NUCLEOSIDES; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 47549096063     PISSN: 0893228X     EISSN: None     Source Type: Journal    
DOI: 10.1021/tx8000219     Document Type: Review

References (109)

1. UNAIDS WHO (2007) AIDS epidemic update.
2. Cohen, D. (2004) HIV/AIDS is spreading fastest in eastern Europe and Asia. BMJ 329, 67.
3. Cohen, J. (2006) HIV/AIDS: Latin America & Caribbean. Overview: The overlooked epidemic. Science 313, 468-469.
4. Teerawattananon, Y., Vos, T., Tangcharoensathien, V., and Mugford, M. (2005) Cost-effectiveness of models for prevention of vertical HIV transmission - Voluntary counseling and testing and choices of drug regimen. Cost Eff. Resour. Alloc. 3, 7.
5. Colebunders, R., Kamya, M. R., Laurence, J., Kambugu, A., Byakwaga, H., et al. (2005) First-line antiretroviral therapy in Africa - How evidence-base are our recommendations? AIDS Rev. 7, 148-154.
6. del Rio, C. (2001) HIV: It's beginning to look like a chronic disease. AIDS Clin. Care 13, 82-83.
7. Navarro, A. (2004) Mitochondrial enzyme activities as biochemical markers of aging. Mol. Aspects Med. 25, 37-48.
8. Wallace, D. C. (2005) A mitochondrial paradigm of metabolic and degenerative diseases, aging, and cancer: A dawn for evolutionary medicine. Annu. Rev. Genet. 39, 359-407.
9. Schapira, A. H. (2006) Mitochondrial disease. Lancet 368, 70-82.
10. Reynolds, T. (2007) From small things. BMJ 335, 747-748.
11. Reich, E., and Luck, D. J. (1966) Replication and inheritance of mitochondrial DNA. Proc. Natl. Acad. Sci. U.S.A. 55, 1600-1608.
12. Copeland, W. C. (2008) Inherited mitochondrial diseases of DNA replication. Annu. Rev. Med. 59, 131-146.
13. Moraes, C. T., Shanske, S., Tritschler, H. J., Aprille, J. R., Andreetta, F., et al. (1991) mtDNA depletion with variable tissue expression: A novel genetic abnormality in mitochondrial diseases. Am. J. Hum. Genet. 48, 492-501.
14. Marin-Garcia, J., and Goldenthal, M. J. (2000) Mitochondrial biogenesis defects and neuromuscular disorders. Pediatr. Neurol. 22, 122-129.
15. McKenzie, R., Fried, M. W., Sallie, R., Conjeevaram, H., Di Bisceglie, A. M., et al. (1995) Hepatic failure and lactic acidosis due to fialuridine (FIAU), an investigational nucleoside analogue for chronic hepatitis B (see comments). N. Engl. J. Med. 333, 1099-1105.
16. Tennant, B. C., Baldwin, B. H., Graham, L. A., Ascenzi, M. A., Hornbuckle, W. E., et al. (1998) Antiviral activity and toxicity of fialuridine in the woodchuck model of hepatitis B virus infection. Hepatology 28, 179-191.
17. Arnaudo, E., Dalakas, M., Shanske, S., Moraes, C. T., DiMauro, S., and Schon, E. A. (1991) Depletion of muscle mitochondrial DNA in AIDS patients with zidovudine-induced myopathy. Lancet 337, 508-510.
18. Lewis, W., Griniuviene, B., Tankersley, K. O., Levine, E. S., Montione, R., et al. (1997) Depletion of mitochondrial DNA, destruction of mitochondria, and accumulation of lipid droplets result from fialuridine treatment in woodchucks (Marmota monax). Lab. Invest. 76, 77-87.
19. Lewis, W., and Dalakas, M. C. (1995) Mitochondrial toxicity of antiviral drugs. Nat. Med. 1, 417-422.
20. Lewis, W., Copeland, W. C., and Day, B. (2001) Mitochondrial DNA depletion, oxidative stress and mutation: Mechanisms of nucleoside reverse transcriptase inhibitor toxicity. Lab. Invest. 81, 777-790.
21. Longo-Mbenza, B., Seghers, K. V., Phuati, M., Bikangi, F. N., and Mubagwa, K. (1998) Heart involvement and HIV infection in African patients: Determinants of survival. Int. J. Cardiol. 64, 63-73.
22. Patel, V. B., Sacoor, Z., Francis, P., Bill, P. L., Bhigjee, A. I., and Connolly, C. (2005) Ischemic stroke in young HIV-positive patients in Kwazulu-Natal, South Africa. Neurology 65, 759-761.
23. Pugliese, A., Isnardi, D., Saini, A., Scarabelli, T., Raddino, R., and Torre, D. (2000) Impact of highly active antiretroviral therapy in HIV-positive patients with cardiac involvement. J. Infect. 40, 282-284.
24. Anderson, D. W., Virmani, R., Reilly, J. M., O'Leary, T., Cunnion, R. E., et al. (1988) Prevalent myocarditis at necropsy in the acquired immunodeficiency syndrome. J. Am. Coll. Cardiol. 11, 792-799.
25. Anderson, D. W., and Virmani, R. (1990) Emerging patterns of heart disease in human immunodeficiency virus infection. Hum. Pathol. 21, 253-259.
26. Cohen, I. S., Anderson, D. W., Virmani, R., Reen, B. M., Macher, A. M., et al. (1986) Congestive cardiomyopathy in association with the acquired immunodeficiency syndrome. N. Engl. J. Med. 315, 628-630.
27. Monsuez, J. J., Escaut, L., Teicher, E., Charniot, J. C., and Vittecoq, D. (2007) Cytokines in HIV-associated cardiomyopathy. Int. J. Cardiol. 120, 150-157.
28. Restrepo, C. S., Diethelm, L., Lemos, J. A., Velasquez, E., Ovella, T. A., et al. (2006) Cardiovascular complications of human immunodeficiency virus infection. Radiographics 26, 213-231.
29. Lewis, W. (2000) Cardiomyopathy in AIDS: A pathophysiological perspective. Prog. Cardiovasc. Dis. 43, 151-170.
30. Lewis, W. (2003) Defective mitochondrial DNA replication and NRTIs: Pathophysiological implications in AIDS cardiomyopathy. Am. J. Physiol. Heart Circ. Physiol. 284, H1-H9.
31. Currie, P. F., Goldman, J. H., Caforio, A. L., Jacob, A. J., Baig, M. K., et al. (1998) Cardiac autoimmunity in HIV related heart muscle disease. Heart 79, 599-604.
32. Zimmerman, F. H., Gustafson, G. M., and Kemp, H. G., Jr. (1987) Recurrent myocardial infarction associated with cocaine abuse in a young man with normal coronary arteries: evidence for coronary artery spasm culminating in thrombosis. J. Am. Coll. Cardiol. 9, 964-968.
33. Felker, G. M., Thompson, R. E., Hare, J. M., Hruban, R. H., Clemetson, D. E., et al. (2000) Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy (see comments). N. Engl. J. Med. 342, 1077-1084.
34. Schulz-Menger, J., Maisch, B., Abdel-Aty, H., and Pankuweit, S. (2007) Integrated biomarkers in cardiomyopathies: Cardiovascular magnetic resonance imaging combined with molecular and immunologic markers - A stepwise approach for diagnosis and treatment. Herz. 32, 458-472.
35. Currie, P. F., Jacob, A. J., Foreman, A. R., Elton, R. A., Brettle, R. P., and Boon, N. A. (1994) Heart muscle disease related to HIV infection: Prognostic implications. BMJ 309, 1605-1607.
36. De Palo, V. A., Millstein, B. H., Mayo, P. H.. Salzman, S. H., and Rosen, M. J. (1995) Outcome of intensive care in patients with HIV infection. Chest 107, 506-510.
37. Neubauer, S. (2007) The failing heart - An engine out of fuel. N. Engl. J. Med. 356, 1140-1151.
38. Ahmad, F., Seidman, J. G., and Seidman, C. E. (2005) The genetic basis for cardiac remodeling. Annu. Rev. Genomics Hum. Genet. 6, 185-216.
39. Del Prete, G., Maggi, E., Pizzolo, G., and Romagnani, S. (1995) CD30, Th2 cytokines and HIV infection: A complex and fascinating link. Immunol. Today 16, 76-80.
40. Grody, W. W., Cheng, L., and Lewis, W. (1990) Infection of the heart by the human immunodeficiency virus. Am. J. Cardiol. 66, 203-206.
41. Rodriguez, E. R., Nasim, S., Hsia, J., Sandin, R. L., Ferreira, A., et al. (1991) Cardiac myocytes and dendritic cells harbor human immunodeficiency virus in infected patients with and without cardiac dysfunction: Detection by multiplex, nested, polymerase chain reaction in individually microdissected cells from right ventricular endomyocardial biopsy tissue. Am. J. Cardiol. 68, 1511-1520.
42. Rebolledo, M. A., Krogstad, P., Chen, F., Shannon, K. M., and Klitzner, T. S. (1998) Infection of human fetal cardiac myocytes by a human immunodeficiency virus-1-derived vector. Circ. Res. 83, 738-742.
43. Fiala, M., Popik, W., Qiao, J. H., Lossinsky, A. S., Alee, T., et al. (2004) HIV-1 induces cardiomyopathyby cardiomyocyte invasion and gp120, Tat, and cytokine apoptotic signaling. Cardiovasc. Toxicol. 4, 97-107.
44. Chen, Z., Siu, B., Ho, Y. S., Vincent, R., Chua, C. C., et al. (1998) Overexpression of MnSOD protects against myocardial ischemia/ reperfusion injury in transgenic mice. J. Mol. Cell. Cardiol. 30, 2281-2289.
45. Lewis, W., Grupp, I. L., Grupp, G., Hoit, B., Morris, R., et al. (2000) Cardiac dysfunction occurs in the HIV-1 transgenic mouse treated with zidovudine. Lab. Invest. 80, 187-197.
46. Lewis, W., Haase, C. P., Raidel, S. M., Russ, R. B., Sutliff, R. L., et al. (2001) Combined antiretroviral therapy causes cardiomyopathy and elevates plasma lactate in transgenic AIDS mice. Lab. Invest. 81, 1527-1536.
47. Domanski, M. J., Sloas, M. M., Follmann, D. A., Scalise, P. P., 3rd, Tucker, E. E., et al. (1995) Effect of zidovudine and didanosine treatment on heart function in children infected with human immunodeficiency virus (see comments). J. Pediatr. 127, 137-146.
48. Herskowitz, A., Willoughby, S. B., Baughman, K. L., Schulman, S. P., and Bartlett, J. D. (1992) Cardiomyopathy associated with antiretroviral therapy in patients with HIV infection: A report of six cases. Ann. Intern. Med. 116, 311-313.
49. Tanuma, J., Ishizaki, A., Gatanaga, H., Kikuchi, Y., Kimura, S., et al. (2003) Dilated cardiomyopathy in an adult Human immunodeficiency virus type 1-positive patient treated with a zidovudine-containing antiretroviral regimen. Clin. Infect Dis. 37, e109-111.
50. d'Amati, G., and Lewis, W. (1994) Zidovudine causes early increases in mitochondrial ribonucleic acid abundance and induces ultrastructural changes in cultured mouse muscle cells. Lab. Invest. 71, 879-884.
51. Frerichs, F. C., Dingemans, K. P., and Brinkman, K. (2002) Cardiomyopathy with mitochondrial damage associated with nucleoside reverse-transcriptase inhibitors. N. Engl. J. Med. 347, 1895-1896.
52. Breuckmann, F., Nassenstein, K., Kondratieva, J., Esser, S., Erbel, R., et al. (2007) MR characterization of cardiac abnormalities in HIV+ individuals with increased BNP levels. Eur. J. Med. Res. 12, 185-190.
53. Neumann, T., Esser, S., Potthoff, A., Pankuweit, S., Neumann, A., et al. (2007) Prevalence and natural history of heart failure in outpatient HIV-infected subjects: Rationale and design of the HIV-HEART study. Eur. J. Med. Res. 12, 243-248.
54. Brinkman, K., ter Hofstede, H. J., Burger, D. M., Smeitink, J. A., and Koopmans, P. P. (1998) Adverse effects of reverse transcriptase inhibitors: Mitochondrial toxicity as common pathway. AIDS 12, 1735-1744.
55. Weissman, J. D., Constantinitis, I., Hudgins, P., and Wallace, D. C. (1992) 31P magnetic resonance spectroscopy suggests impaired mitochondrial function in AZT-treated HIV-infected patients. Neurology 42, 619-623.
56. Lewis, W., Meyer, R. R., Simpson, J. F., Colacino, J. M., and Perrino, F. W. (1994) Mammalian DNA polymerases alpha, beta, gamma, delta, and epsilon incorporate fialuridine (FIAU) monophosphate into DNA and are inhibited competitively by FIAU Triphosphate. Biochemistry 33, 14620-14634.
57. Institute of Medicine (U.S.). Committee to Review the Fialuridine (FIAU/RAC) Clinical Trials (1995) Review of the Fialuridine (FIAU) Clinical Trials, Vol. IX, 269 pp, National Academy Press, Washington, DC.
58. Comereski, C. R., Kelly, W. A., Davidson, T. J., Warner, W. A., Hopper, L. D., and Oleson, F. B. (1993) Acute cardiotoxicity of nucleoside analogs FddA and FddI in rats. Fundam. Appl. Toxicol. 20, 360-364.
59. Ruxrungtham, K., Boone, E., Ford, H., Jr., Driscoll, J. S., Davey, R. T., Jr., and Lane, H. C. (1996) Potent activity of 2′-beta-fluoro-2′, 3′-dideoxyadenosine against human immunodeficiency virus type 1 infection in hu-PBL-SCID mice. Antimicrob. Agents Chemother. 40, 2369-2374.
60. Saitoh, A., Fenton, T., Alvero, C., Fletcher, C. V., and Spector, S. A. (2007) Impact of nucleoside reverse transcriptase inhibitors on mitochondria in HIV-1 infected children receiving HAART. Antimicrob. Agents Chemother. 51, 4236-4242.
61. Blanche, S., Tardieu, M., Benhammou, V., Warszawski, J., and Rustin, P. (2006) Mitochondrial dysfunction following perinatal exposure to nucleoside analogues. AIDS 20, 1685-1690.
62. Lopriore, E., Rozendaal, L., Gelinck, L. B., Bokenkamp, R., Boelen, C. C., and Walther, F. J. (2007) Twins with cardiomyopathy and complete heart block born to an HIV-infected mother treated with HAART. AIDS 21, 2564-2565.
63. Lipshultz, S. E., Easley, K. A., Orav, E. J., Kaplan, S., Starc, T. J., et al. (2002) Cardiovascular status of infants and children of women infected with HIV-1 (P(2)C(2) HIV): A cohort study. Lancet 360, 368-373.
64. Olivero, O. A., Anderson, L. M., Diwan, B. A., Haines, D. C., Harbaugh, S. W., et al. (1997) Transplacental effects of 3′-azido-2′,3′- dideoxythymidine (AZT): tumorigenicity in mice and genotoxicity in mice and monkeys (see comments). J. Natl. Cancer. Inst. 89, 1602-1608.
65. Foster, C., and Lyall, H. (2008) HIV and mitochondrial toxicity in children. J. Antimicrob. Chemother. 61, 8-12.
66. Chan, S. S., Santos, J. H., Meyer, J. N., Mandavilli, B. S., Cook, D. L., Jr., et al. (2007) Mitochondrial toxicity in hearts of CD-1 mice following perinatal exposure to AZT, 3TC, or AZT/3TC in combination. Environ. Mol. Mutagen. 48, 190-200.
67. Walker, D. M., Poirier, M. C., Campen, M. J., Cook, D. L., Jr., Divi, R. L., et al. (2004) Persistence of mitochondrial toxicity in hearts of female B6C3F1 mice exposed in utero to 3′-azido-3′-deoxythymidine. Cardiovasc. Toxicol. 4, 133-153.
68. Levy, J. A. (1998) HIV and the Pathogenesis of AIDS, ASM Press, Washington, DC.
69. Mitsuya, H., Weinhold, K. J., Furman, P. A., St. Clair, M. H., Lehrman, S. N., et al. (1985) 3′-Azido-3′-deoxythymidine (BW A509U): an antiviral agent that inhibits the infectivity and cytopathic effect of human T-lymphotropic virus type III/lymphadenopathy-associated virus in vitro. Proc. Natl. Acad. Sci. U.S.A. 82, 7096-7100.
70. Richman, D. D., Fischl, M. A., Grieco, M. H., Gottlieb, M. S., Volberding, P. A., et al. (1987) The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. N. Engl. J. Med. 317, 192-197.
71. Lewis, W., Gonzalez, B., Chomyn, A., and Papoian, T. (1992) Zidovudine induces molecular, biochemical, and ultrastructural changes in rat skeletal muscle mitochondria. J. Clin. Invest. 89, 1354-1360.
72. Collier, A. C., Bozzette, S., Coombs, R. W., Causey, D. M., Schoenfeld, D. A., et al. (1990) A pilot study of low-dose zidovudine in human immunodeficiency virus infection. N. Engl. J. Med. 323, 1015-1021.
73. Chen, C. H., and Cheng, Y. C. (1989) Delayed cytotoxicity and selective loss of mitochondrial DNA in cells treated with the anti-human immunodeficiency virus compound 2′,3′-dideoxycytidine. J. Biol. Chem. 264, 11934-11937.
74. Wright, G. E., and Brown, N. C. (1990) Deoxyribonucleotide analogs as inhibitors and substrates of DNA polymerases. Pharmacol. Ther. 47, 447-497.
75. Brinkman, K. (2000) Editorial response: Hyperlactatemia and hepatic steatosis as features of mitochondrial toxicity of nucleoside analogue reverse transcriptase inhibitors. Clin. Infect. Dis. 31, 167-169.
76. Kakuda, T. N. (2000) Pharmacology of nucleoside and nucleotide reverse transcriptase inhibitor-induced mitochondrial toxicity (in process citation). Clin. Ther. 22, 685-708.
77. Lewis, W., and Tankersley, K. O. (1995) Triphosphorylated fialuridine and metabolites inhibit cardiac mitochondrial DNA polymerase gamma (DNA polymerase-gamma): Aalternative substrates for thymidine triphosphate (dTTP). Circulation 92, 1186.
78. Lim, S. E., Longley, M. J., and Copeland, W. C. (1999) The mitochondrial p55 accessory subunit of human DNA polymerase gamma enhances DNA binding, promotes processive DNA synthesis, and confers N-ethylmaleimide resistance. J. Biol. Chem. 274, 38197-38203.
79. Longley, M. J., Nguyen, D., Kunkel, T. A., and Copeland, W. C. (2001) The fidelity of human DNA polymerase gamma with and without exonucleolytic proofreading and the p55 accessory subunit. J. Biol. Chem. 276, 38555-38562.
80. Copeland, W. C., Chen, M. S., and Wang, T. S. (1992) Human DNA polymerases alpha and beta are able to incorporate anti-HIV deoxynucleotides into DNA. J. Biol. Chem. 267, 21459-21464.
81. Huang, P., Farquhar, D., and Plunkett, W. (1990) Selective action of 3′-azido-3′-deoxythymidine 5′-triphosphate on viral reverse transcriptases and human DNA polymerases. J. Biol. Chem. 265, 11914-11918.
82. Huang, P., Farquhar, D., and Plunkett, W. (1992) Selective action of 2′,3′-didehydro-2′,3′-dideoxythymidine triphosphate on human immunodeficiency virus reverse transcriptase and human DNA polymerases. J. Biol. Chem. 267, 2817-2822.
83. Kaguni, L. S., Wernette, C. M., Conway, M. C., and Yang-Cashman, P. (1988) Structural and catalytic features of the mitochondrial DNA polymerase from Drosophila melanogaster embryos. Eukaryotic DNA Replication, pp 425-432, Cold Spring Harbor Laboratories, Cold Spring Harbor, NY.
84. Martin, J. L., Brown, C. E., Matthews-Davis, N., and Reardon, J. E. (1994) Effects of antiviral nucleoside analogs on human DNA polymerases and mitochondrial DNA synthesis. Antimicrob. Agents Chemother. 38, 2743-2749.
85. Nickel, W., Austermann, S., Bialek, G., and Grosse, F. (1992) Interactions of azidothymidine triphosphate with the cellular DNA polymerases alpha, delta, and epsilon and with DNA primase. J. Biol. Chem. 267, 848-854.
86. Lewis, W., Simpson, J. F., and Meyer, R. R. (1994) Cardiac mitochondrial DNA polymerase-gamma is inhibited competitively and noncompetitively by phosphorylated zidovudine. Circ. Res. 74, 344-348.
87. Lim, S. E., and Copeland, W. C. (2001) Differential incorporation and removal of antiviral deoxynucleotides by human DNA polymerase gamma. J. Biol. Chem. 276, 23616-23623.
88. Johnson, A. A., Ray, A. S., Hanes, J., Suo, Z., Colacino, J. M., et al. (2001) Toxicity of antiviral nucleoside analogs and the human mitochondrial DNA polymerase. J. Biol. Chem. 276, 40847-40857.
89. Lewis, W., Day, B. J., and Copeland, W. C. (2003) Mitochondrial toxicity of nrti antiviral drugs: an integrated cellular perspective. Nat. Rev. Drug Discovery 2, 812-822.
90. Klotman, P. E., and Notkins, A. L. (1996) Transgenic models of human immunodeficiency virus type-1. Curr. Top. Microbiol. Immunol. 206, 197-222.
91. Kopp, J. B., Rooney, J. F., Wohlenberg, C., Dorfman, N., Marinos, N. J., et al. (1993) Cutaneous disorders and viral gene expression in HIV-1 transgenic mice. AIDS Res. Hum. Retroviruses 9, 267-275.
92. Palmieri, F. (1994) Mitochondrial carrier proteins. FEBS Lett. 346, 48-54.
93. Dolce, V., Fiermonte, G., Runswick, M. J., Palmieri, F., and Walker, J. E. (2001) The human mitochondrial deoxynucleotide carrier and its role in the toxicity of nucleoside antivirals. Proc. Natl. Acad. Sci. USA. 98, 2284-2288.
94. Palmieri, F. (2004) The mitochondrial transporter family (SLC25): Physiological and pathological implications. Pflugers Arch. 447, 689-709.
95. Lewis, W., Haase, C. P., Miller, Y. K., Ferguson, B., Stuart, T., et al. (2005) Transgenic expression of the deoxynucleotide carrier causes mitochondrial damage that is enhanced by NRTIs for AIDS. Lab. Invest. 85, 972-981.
96. Lewis, W., Kohler, J. J., Hosseini, S. H., Haase, C. P., Copeland, W. C., et al. (2006) Antiretroviral nucleosides, deoxynucleotide carrier and mitochondrial DNA: Evidence supporting the DNA pol gamma hypothesis. AIDS 20, 675-684.
97. Lindhurst, M. J., Fiermonte, G., Song, S., Struys, E., De Leonardis, F., et al. (2006) Knockout of Slc25a19 causes mitochondrial thiamine pyrophosphate depletion, embryonic lethality, CNS malformations, and anemia. Proc. Natl. Acad. Sci. U.S.A. 103, 15927-15932.
98. Eriksson, S., Munch-Petersen, B., Kierdaszuk, B., and Arner, E. (1991) Expression and substrate specificities of human thymidine kinase 1, thymidine kinase 2 and deoxycytidine kinase. Adv. Exp. Med. Biol. 309B, 239-243.
99. Eriksson, S., Munch-Petersen, B., Johansson, K., and Eklund, H. (2002) Structure and function of cellular deoxyribonucleoside kinases. Cell. Mol. Life Sci. 59, 1327-1346.
100. Hosseini, S. H., Kohler, J. J., Haase, C. P., Tioleco, N., Stuart, T., et al. (2007) Targeted transgenic overexpression of mitochondrial thymidine kinase (TK2) alters mitochondrial DNA (mtDNA) and mitochondrial polypeptide abundance: Transgenic TK2, mtDNA, and antiretrovirals. Am. J. Pathol. 170, 865-874.
101. Susan-Resiga, D., Bentley, A. T., Lynx, M. D., LaClair, D. D., and McKee, E. E. (2007) Zidovudine inhibits thymidine phosphorylation in the isolated perfused rat heart. Antimicrob. Agents Chemother. 51, 1142-1149.
102. Trifunovic, A., Wredenberg, A., Falkenberg, M., Spelbrink, J. N., Rovio, A. T., et al. (2004) Premature ageing in mice expressing defective mitochondrial DNA polymerase. Nature 429, 417-423.
103. Zhang, D., Ezekiel, U. R., Chang, S. W., and Zassenhaus, H. P. (2005) Gene expression profile in dilated cardiomyopathy caused by elevated frequencies of mitochondrial DNA mutations in the mouse heart. Cardiovasc. Pathol. 14, 61-69.
104. Zhang, D., Mott, J. L., Chang, S. W., Stevens, M., Mikolajczak, P., and Zassenhaus, H. P. (2005) Mitochondrial DNA mutations activate programmed cell survival in the mouse heart. Am. J. Physiol. Heart Circ. Physiol. 288, H2476-2483.
105. Lewis, W., Day, B. J., Kohler, J. J., Hosseini, S. H., Chan, S. S., et al. (2007) Decreased mtDNA, oxidative stress, cardiomyopathy, and death from transgenic cardiac targeted human mutant polymerase gamma. Lab. Invest. 87, 326-335.
106. Lund, K. C., and Wallace, K. B. (2008) Adenosine 3′,5′-cyclic monophosphate (cAMP)-dependent phosphoregulation of mitochondrial complex I is inhibited by nucleoside reverse transcriptase inhibitors. Toxicol. Appl. Pharmacol. 226, 94-106.
107. Lund, K. C., and Wallace, K. B. (2004) Direct effects of nucleoside reverse transcriptase inhibitors on rat cardiac mitochondrial bioenergetics. Mitochondrion 4, 193-202.
108. Igoudjil, A., Abbey-Toby, A., Begriche, K., Grodet, A., Chataigner, K., et al. (2007) High doses of stavudine induce fat wasting and mild liver damage without impairing mitochondrial respiration in mice. Antiviral Ther. 12, 389-400.
109. Stankov, M. V., Lucke, T., Das, A. M., Schmidt, R. E., and Behrens, G. M. (2007) Relationship of mitochondrial DNA depletion and respiratory chain activity in preadipocytes treated with nucleoside reverse transcriptase inhibitors. Antiviral Ther. 12, 205-216.